AURA · Aura Biosciences, Inc. · Executive Compensation

$6.30 -0.11 (-1.64%) At close · Oct 29 Q1 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$652.82M

103.70M

Volume · Oct 29 769.98K Avg daily vol (3M) 856.21K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Elisabet de los Pinos	President, Chief Executive Officer and Director	$431,816	$70,538	$1,040,998	$5,098,639	$157,462	$16,803	$6,816,256
Cadmus C. Rich	Chief Medical Officer and Head of Research & Development	$392,816	—	$367,500	$1,466,906	$154,002	$17,400	$2,398,624
Julie B. Feder	Chief Financial Officer	$360,407	—	$367,500	$1,466,906	$145,042	—	$2,339,855

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Elisabet de los Pinos	President, Chief Executive Officer and Director	$394,890	$148,913	—	$533,997	—	$17,100	$1,094,900
Cadmus C. Rich	Chief Medical Officer and Head of Research & Development	$377,280	$124,488	—	$113,498	—	$17,100	$632,366
Julie B. Feder	Chief Financial Officer	$343,216	$113,249	—	$95,877	—	—	$552,342

Executive changes

Person	Role	Change	Effective	Filed
Anthony Gibney	Chief Financial and Business Officer	Resigned	2026-09-01	2026-08-11
Susan Abu-Absi	Chief Operating Officer	Appointed	2026-08-10	2026-08-11
Jeremy Bender, Ph.D., M.B.A.	Class II director	Appointed	2026-07-07	2026-07-08
Natalie Holles	Class I director	Appointed	2026-04-30	2026-05-04
Natalie Holles	Chief Executive Officer and President	Appointed	2026-04-30	2026-05-04
Anthony Gibney	Chief Financial and Business Officer	Appointed	2025-05-13	2025-05-15
Teresa Marie Bitetti	Class II director	Appointed	2025-03-31	2025-04-02
Julie Feder	Chief Financial Officer	Resigned	2024-10-25	2024-09-27
Raj Parekh, Ph.D.	member of the Company's board of directors	Resigned	2024-06-20	2024-04-15
Cadmus Rich, M.D.	Chief Medical Officer	Resigned	2023-10-16	2023-10-02
J. Jill Hopkins, M.D.	Chief Medical Officer and President of Research & Development	Appointed	2023-10-16	2023-10-02
Mark De Rosch	Chief Operating Officer	Resigned	2023-04-30	2023-04-04

Leadership

Elisabet de los Pinos CEO, Board Member
Natalie Holles CEO, Board Member
Amy Elazzouzi CFO, Chief Accounting Officer
Anthony Gibney CFO
Julie B. Feder CFO
Mark De Rosch COO
Susan Abu-Absi COO
Mark Plavsic CTO
Conor Kilroy General Counsel
David Johnson Board Member
Jeremy Bender, Ph.D., M.B.A. Board Member
Teresa Marie Bitetti Board Member

Key facts CIK 1501796 CUSIP 05153U107 13F (30d) 26 filings 26 filers Visit website Investor relations